Vaccine Info

Ad5-EBOV Ebola Vaccine

Authored by
Last reviewed
April 25, 2022

CanSinoBio Ad5-EBOV Ebola Vaccine Description 2022

CanSinBio Ad5-EBOV is an adenovirus type 5 recombinant vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. In addition, ad5-EBOV is manufactured as a lyophilized powder, highly stable, and does not require storage at ultra-low temperatures. This feature renders it viable for use in resource-limited tropical areas.

CanSino Biologics's Ad5-EBOV received NDA approval in China in October 2017. Ad5-EBOV has shown an acceptable stability profile and does not require ultra-low temperature storage conditions.

In 2014, a single-center, double-blind, placebo-control, dose-escalation phase 1 clinical trial was performed in Taizhou, China. The findings showed that the Ad5-EBOV vaccine was safe and robustly immunogenic. In this add-in study, the investigators intended to evaluate the safety and immunogenicity of a booster dose of the recombinant Ebola adenovirus vector vaccine (Ad5-EBOV) in healthy adults after primary immunization. The investigators expect that boosting immunization with the same vaccine for primary immunization is possible and could confer longer-lived protection when needed.

In July 2015, the First Affiliated Hospital of Zhejiang University launched a single-center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged 18-60 years in China.

CanSino Biologics Inc.'s Ad5-EBOV vaccine is currently in China's national stockpile. In addition, CanSinoBio announced its new brand identity on April 24, 2022.

CanSinoBio Ad5-EBOV Ebola Vaccine Indication

Ad5-EBOV is indicated to prevent an infection of the Ebola disease. One shot of the high dose vaccine could mount a glycoprotein-specific humoral and T-cell response against the Ebola virus in 14 days. In addition, the company says, 'As compared to competing products from multinational companies, our Ad5-EBOV has shown a better stability profile and does not require ultra-low temperature storage conditions.'

CanSinoBio Ad5-EBOV Ebola Vaccine News 2014 - 2022

April 23, 2022 - reported a man infected with Ebola disease died in the north western province of the DRC.

August 12, 2020 - CanSino Biologics Inc. announced that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company.

October 24, 2017 - Ad5-EBOV, the recombinant adenovirus vector-based vaccine, is the first Ebola shot based on the strain behind the recent epidemic in West Africa in 2014—the deadliest outbreak in recorded history.

October 14, 2014 - A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization.

CanSinoBio Ad5-EBOV Ebola Vaccine Clinical Trials

Yu Xuefeng, chairman and CEO of CanSinoBIO, points out that from a concept to an approved product, the development of the Ad5-EBOV vaccine took just a little more than three years, demonstrating CanSinoBIO’s strong capability for efficiently pushing a candidate through R&D and completing pre-clinical studies and clinical trials.